Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARICADE-DELAY
2025-521797-34-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Time from baseline to diagnosis of stage 3 type 1 diabetes. Planned start Jan 2026; status: authorised.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-521797-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521797-34-00.